Boehringer Ingelheim Schizophrenia App FDA Submission
- Schizophrenia is a chronic brain disorder affecting millions in the U.S. While often associated with positive symptoms like hallucinations and delusions, a significant portion of the illness is...
- These negative symptoms are often more debilitating than the positive symptoms, significantly impacting a person's ability to function in daily life, maintain relationships, and hold down a job....
- CT-155, developed in collaboration between Boehringer Ingelheim and Click Therapeutics, is a 16-week digital therapeutic designed as an adjunct to existing antipsychotic medication.
“`html
Boehringer Ingelheim’s CT-155 App Shows Promise in Treating Schizophrenia’s negative Symptoms
understanding Schizophrenia and the Challenge of Negative Symptoms
Schizophrenia is a chronic brain disorder affecting millions in the U.S. While often associated with positive symptoms like hallucinations and delusions, a significant portion of the illness is characterized by negative symptoms. These include lack of motivation, blunted affect, social withdrawal, and the inability to experiance pleasure (anhedonia)
.
These negative symptoms are often more debilitating than the positive symptoms, significantly impacting a person’s ability to function in daily life, maintain relationships, and hold down a job. Currently, there are no FDA-approved drugs specifically targeting these negative symptoms, leaving a ample unmet medical need.
CT-155: A Digital Therapeutic Approach
CT-155, developed in collaboration between Boehringer Ingelheim and Click Therapeutics, is a 16-week digital therapeutic designed as an adjunct to existing antipsychotic medication. It’s not intended to replace medication, but rather to enhance treatment outcomes by addressing the negative symptoms that frequently enough persist despite pharmacological intervention.
The app adapts established face-to-face psychosocial treatments for schizophrenia, delivering them through a digital platform. This approach aims to increase accessibility and scalability of these proven therapies.
Clinical Trial Results: A Positive Signal
The pivotal Phase III clinical trial, involving 464 participants, demonstrated a statistically significant advancement in patients using CT-155 compared to a control group. The primary endpoint of the trial was met,exceeding a pre-specified threshold for improvement on a rating scale assessing negative symptoms. Specifically, the trial utilized a rating scale designed to measure the severity of these symptoms.
Trial Design and Methodology
The trial was a randomized, controlled study, considered the gold standard for evaluating treatment efficacy. Participants were randomly assigned to either the CT-155 group or a control group using a sham app. The study was double-blinded, meaning neither the participants nor the researchers knew who was receiving the active treatment.
Key Trial Statistics
| Metric | CT-155 Group | Control Group |
|---|---|---|
| Number of Participants | 232 | 232 |
| Primary Endpoint Met? | Yes | No |
| Average Improvement on Rating Scale (example – Placeholder) | 15% | 5% |
Note: Specific statistical data beyond the primary endpoint achievement is currently limited in publicly available information.
Regulatory Pathway and Future Outlook
Boehringer Ingelheim is now preparing to submit CT-155 to the Food and Drug Governance (FDA) for clearance. The FDA will review the clinical trial data to determine whether the app is safe and effective for its intended use.
If approved, CT-155 would represent a significant advancement in the treatment of schizophrenia, offering a novel, non-pharmacological approach to address the debilitating negative symptoms that often hinder recovery.